These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34245854)

  • 1. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
    Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
    Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
    Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
    Chen Z; Vallega KA; Chen H; Zhou J; Ramalingam SS; Sun SY
    Pharmacol Res; 2022 Jan; 175():105998. PubMed ID: 34826601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 12. Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun SY
    Mol Oncol; 2020 Apr; 14(4):882-895. PubMed ID: 32003107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
    Ma G; Deng Y; Qian L; Vallega KA; Zhang G; Deng X; Owonikoko TK; Ramalingam SS; Fang DD; Zhai Y; Sun SY
    Oncogene; 2022 Mar; 41(12):1691-1700. PubMed ID: 35102249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.
    Tanaka K; Yu HA; Yang S; Han S; Selcuklu SD; Kim K; Ramani S; Ganesan YT; Moyer A; Sinha S; Xie Y; Ishizawa K; Osmanbeyoglu HU; Lyu Y; Roper N; Guha U; Rudin CM; Kris MG; Hsieh JJ; Cheng EH
    Cancer Cell; 2021 Sep; 39(9):1245-1261.e6. PubMed ID: 34388376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase 3 Inhibition Overcomes
    Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
    Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
    [No Abstract]   [Full Text] [Related]  

  • 19. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.